Which has better valuation & earnings, MEDP or CHE?

Medpace has higher revenue and earnings than Chemed. Chemed is trading at a lower price-to-earnings ratio than Medpace, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Medpace $2.53B 6.75 $451.12M $17.06 35.88 Chemed $2.53B 2.58 $265.24M $19.91 25.07

Is MEDP or CHE more profitable?

Medpace has a net margin of 17.67% compared to Chemed's net margin of 10.60%. Medpace's return on equity of 110.15% beat Chemed's return on equity. Company Net Margins Return on Equity Return on Assets Medpace 17.67% 110.15% 24.84% Chemed 10.60% 31.77% 18.90%

Does the media favor MEDP or CHE?

In the previous week, Medpace had 1 more articles in the media than Chemed. MarketBeat recorded 7 mentions for Medpace and 6 mentions for Chemed. Medpace's average media sentiment score of 0.68 beat Chemed's score of 0.15 indicating that Medpace is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Medpace 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Chemed 0 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable earnings & valuation, DGX or CHE?

Quest Diagnostics has higher revenue and earnings than Chemed. Quest Diagnostics is trading at a lower price-to-earnings ratio than Chemed, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Quest Diagnostics $11.04B 2.31 $992M $9.42 24.53 Chemed $2.53B 2.58 $265.24M $19.91 25.07

Is DGX or CHE more profitable?

Chemed has a net margin of 10.60% compared to Quest Diagnostics' net margin of 9.18%. Chemed's return on equity of 31.77% beat Quest Diagnostics' return on equity. Company Net Margins Return on Equity Return on Assets Quest Diagnostics 9.18% 16.01% 7.27% Chemed 10.60% 31.77% 18.90%

Does the media refer more to DGX or CHE?

In the previous week, Quest Diagnostics and Quest Diagnostics both had 6 articles in the media. Quest Diagnostics' average media sentiment score of 0.49 beat Chemed's score of 0.15 indicating that Quest Diagnostics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Quest Diagnostics 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Chemed 0 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher valuation & earnings, CHE or LH?

Labcorp has higher revenue and earnings than Chemed. Chemed is trading at a lower price-to-earnings ratio than Labcorp, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Chemed $2.53B 2.58 $265.24M $19.91 25.07 Labcorp $13.95B 1.81 $876.50M $12.09 25.81

Is CHE or LH more profitable?

Chemed has a net margin of 10.60% compared to Labcorp's net margin of 6.99%. Chemed's return on equity of 31.77% beat Labcorp's return on equity. Company Net Margins Return on Equity Return on Assets Chemed 10.60% 31.77% 18.90% Labcorp 6.99% 16.74% 7.81%

Does the media refer more to CHE or LH?

In the previous week, Chemed had 2 more articles in the media than Labcorp. MarketBeat recorded 6 mentions for Chemed and 4 mentions for Labcorp. Labcorp's average media sentiment score of 0.48 beat Chemed's score of 0.15 indicating that Labcorp is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Chemed 0 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Labcorp 0 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher earnings & valuation, CHE or GH?

Chemed has higher revenue and earnings than Guardant Health. Guardant Health is trading at a lower price-to-earnings ratio than Chemed, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Chemed $2.53B 2.58 $265.24M $19.91 25.07 Guardant Health $982.02M 22.89 -$416.28M -$3.49 N/A

Is CHE or GH more profitable?

Chemed has a net margin of 10.60% compared to Guardant Health's net margin of -38.33%. Chemed's return on equity of 31.77% beat Guardant Health's return on equity. Company Net Margins Return on Equity Return on Assets Chemed 10.60% 31.77% 18.90% Guardant Health -38.33% N/A -25.40%

Does the media favor CHE or GH?

In the previous week, Guardant Health had 3 more articles in the media than Chemed. MarketBeat recorded 9 mentions for Guardant Health and 6 mentions for Chemed. Guardant Health's average media sentiment score of 0.27 beat Chemed's score of 0.15 indicating that Guardant Health is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Chemed 0 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Guardant Health 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral

Which has better earnings and valuation, CHE or TEM?

Chemed has higher revenue and earnings than Tempus AI. Tempus AI is trading at a lower price-to-earnings ratio than Chemed, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Chemed $2.53B 2.58 $265.24M $19.91 25.07 Tempus AI $1.43B 8.94 -$245.03M -$1.44 N/A

Is CHE or TEM more profitable?

Chemed has a net margin of 10.60% compared to Tempus AI's net margin of -17.77%. Chemed's return on equity of 31.77% beat Tempus AI's return on equity. Company Net Margins Return on Equity Return on Assets Chemed 10.60% 31.77% 18.90% Tempus AI -17.77% -50.28% -10.33%

Does the media favor CHE or TEM?

In the previous week, Tempus AI had 5 more articles in the media than Chemed. MarketBeat recorded 11 mentions for Tempus AI and 6 mentions for Chemed. Tempus AI's average media sentiment score of 0.82 beat Chemed's score of 0.15 indicating that Tempus AI is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Chemed 0 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Tempus AI 5 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Chemed (CHE) Competitors

$499.14 +0.89 (+0.18%)

Closing price 10/9/2026 03:59 PM Eastern

Extended Trading

$492.57 -6.57 (-1.32%)

As of 10/9/2026 07:30 PM Eastern

Compare

CHE vs. MEDP, DGX, LH, GH, and TEM

Should you buy Chemed stock or one of its competitors? Chemed's main competitors and comparable companies include Medpace (MEDP), Quest Diagnostics (DGX), Labcorp (LH), Guardant Health (GH), and Tempus AI (TEM). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare" sector.

How does Chemed compare to Medpace?

Medpace (NASDAQ:MEDP) and Chemed (NYSE:CHE) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, risk, analyst recommendations, valuation, institutional ownership, profitability and media sentiment.

Medpace presently has a consensus price target of $607.73, suggesting a potential downside of 0.71%. Chemed has a consensus price target of $554.60, suggesting a potential upside of 11.11%. Given Chemed's stronger consensus rating and higher possible upside, analysts clearly believe Chemed is more favorable than Medpace.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Medpace	0 Sell rating(s)	10 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.23
Chemed	0 Sell rating(s)	5 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.29

Medpace has a net margin of 17.67% compared to Chemed's net margin of 10.60%. Medpace's return on equity of 110.15% beat Chemed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Medpace	17.67%	110.15%	24.84%
Chemed	10.60%	31.77%	18.90%

In the previous week, Medpace had 1 more articles in the media than Chemed. MarketBeat recorded 7 mentions for Medpace and 6 mentions for Chemed. Medpace's average media sentiment score of 0.68 beat Chemed's score of 0.15 indicating that Medpace is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Medpace	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Chemed	0 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

78.0% of Medpace shares are held by institutional investors. Comparatively, 95.9% of Chemed shares are held by institutional investors. 20.5% of Medpace shares are held by company insiders. Comparatively, 3.3% of Chemed shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Medpace has higher revenue and earnings than Chemed. Chemed is trading at a lower price-to-earnings ratio than Medpace, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Medpace	$2.53B	6.75	$451.12M	$17.06	35.88
Chemed	$2.53B	2.58	$265.24M	$19.91	25.07

Medpace has a beta of 1.18, indicating that its stock price is 18% more volatile than the broader market. Comparatively, Chemed has a beta of 0.51, indicating that its stock price is 49% less volatile than the broader market.

Summary

Medpace beats Chemed on 12 of the 16 factors compared between the two stocks.

How does Chemed compare to Quest Diagnostics?

Quest Diagnostics (NYSE:DGX) and Chemed (NYSE:CHE) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, earnings, risk, profitability, analyst recommendations, institutional ownership, media sentiment and dividends.

Quest Diagnostics has higher revenue and earnings than Chemed. Quest Diagnostics is trading at a lower price-to-earnings ratio than Chemed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Quest Diagnostics	$11.04B	2.31	$992M	$9.42	24.53
Chemed	$2.53B	2.58	$265.24M	$19.91	25.07

Quest Diagnostics pays an annual dividend of $3.44 per share and has a dividend yield of 1.5%. Chemed pays an annual dividend of $2.80 per share and has a dividend yield of 0.6%. Quest Diagnostics pays out 36.5% of its earnings in the form of a dividend. Chemed pays out 14.1% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Quest Diagnostics has increased its dividend for 14 consecutive years and Chemed has increased its dividend for 16 consecutive years.

Quest Diagnostics currently has a consensus target price of $237.85, suggesting a potential upside of 2.93%. Chemed has a consensus target price of $554.60, suggesting a potential upside of 11.11%. Given Chemed's higher possible upside, analysts clearly believe Chemed is more favorable than Quest Diagnostics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Quest Diagnostics	0 Sell rating(s)	6 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.58
Chemed	0 Sell rating(s)	5 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.29

Quest Diagnostics has a beta of 0.54, suggesting that its stock price is 46% less volatile than the broader market. Comparatively, Chemed has a beta of 0.51, suggesting that its stock price is 49% less volatile than the broader market.

In the previous week, Quest Diagnostics and Quest Diagnostics both had 6 articles in the media. Quest Diagnostics' average media sentiment score of 0.49 beat Chemed's score of 0.15 indicating that Quest Diagnostics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Quest Diagnostics	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Chemed	0 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

88.1% of Quest Diagnostics shares are held by institutional investors. Comparatively, 95.9% of Chemed shares are held by institutional investors. 0.9% of Quest Diagnostics shares are held by insiders. Comparatively, 3.3% of Chemed shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Chemed has a net margin of 10.60% compared to Quest Diagnostics' net margin of 9.18%. Chemed's return on equity of 31.77% beat Quest Diagnostics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Quest Diagnostics	9.18%	16.01%	7.27%
Chemed	10.60%	31.77%	18.90%

Summary

Chemed beats Quest Diagnostics on 11 of the 19 factors compared between the two stocks.

How does Chemed compare to Labcorp?

Chemed (NYSE:CHE) and Labcorp (NYSE:LH) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, valuation, dividends, risk, profitability, analyst recommendations, media sentiment and institutional ownership.

Chemed currently has a consensus price target of $554.60, indicating a potential upside of 11.11%. Labcorp has a consensus price target of $337.73, indicating a potential upside of 8.25%. Given Chemed's higher possible upside, equities research analysts clearly believe Chemed is more favorable than Labcorp.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Chemed	0 Sell rating(s)	5 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.29
Labcorp	0 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.75

Chemed has a net margin of 10.60% compared to Labcorp's net margin of 6.99%. Chemed's return on equity of 31.77% beat Labcorp's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Chemed	10.60%	31.77%	18.90%
Labcorp	6.99%	16.74%	7.81%

Chemed pays an annual dividend of $2.80 per share and has a dividend yield of 0.6%. Labcorp pays an annual dividend of $2.88 per share and has a dividend yield of 0.9%. Chemed pays out 14.1% of its earnings in the form of a dividend. Labcorp pays out 23.8% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Chemed has raised its dividend for 16 consecutive years.

Chemed has a beta of 0.51, suggesting that its stock price is 49% less volatile than the broader market. Comparatively, Labcorp has a beta of 0.87, suggesting that its stock price is 13% less volatile than the broader market.

95.9% of Chemed shares are owned by institutional investors. Comparatively, 95.9% of Labcorp shares are owned by institutional investors. 3.3% of Chemed shares are owned by insiders. Comparatively, 0.8% of Labcorp shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Labcorp has higher revenue and earnings than Chemed. Chemed is trading at a lower price-to-earnings ratio than Labcorp, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Chemed	$2.53B	2.58	$265.24M	$19.91	25.07
Labcorp	$13.95B	1.81	$876.50M	$12.09	25.81

In the previous week, Chemed had 2 more articles in the media than Labcorp. MarketBeat recorded 6 mentions for Chemed and 4 mentions for Labcorp. Labcorp's average media sentiment score of 0.48 beat Chemed's score of 0.15 indicating that Labcorp is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Chemed	0 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Labcorp	0 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Chemed beats Labcorp on 10 of the 19 factors compared between the two stocks.

How does Chemed compare to Guardant Health?

Chemed (NYSE:CHE) and Guardant Health (NASDAQ:GH) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, media sentiment, risk, valuation, earnings and dividends.

Chemed has a beta of 0.51, meaning that its stock price is 49% less volatile than the broader market. Comparatively, Guardant Health has a beta of 1.58, meaning that its stock price is 58% more volatile than the broader market.

Chemed has higher revenue and earnings than Guardant Health. Guardant Health is trading at a lower price-to-earnings ratio than Chemed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Chemed	$2.53B	2.58	$265.24M	$19.91	25.07
Guardant Health	$982.02M	22.89	-$416.28M	-$3.49	N/A

Chemed currently has a consensus price target of $554.60, indicating a potential upside of 11.11%. Guardant Health has a consensus price target of $189.38, indicating a potential upside of 13.08%. Given Guardant Health's stronger consensus rating and higher possible upside, analysts plainly believe Guardant Health is more favorable than Chemed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Chemed	0 Sell rating(s)	5 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.29
Guardant Health	1 Sell rating(s)	0 Hold rating(s)	23 Buy rating(s)	1 Strong Buy rating(s)	2.96

95.9% of Chemed shares are held by institutional investors. Comparatively, 92.6% of Guardant Health shares are held by institutional investors. 3.3% of Chemed shares are held by insiders. Comparatively, 5.6% of Guardant Health shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Chemed has a net margin of 10.60% compared to Guardant Health's net margin of -38.33%. Chemed's return on equity of 31.77% beat Guardant Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Chemed	10.60%	31.77%	18.90%
Guardant Health	-38.33%	N/A	-25.40%

In the previous week, Guardant Health had 3 more articles in the media than Chemed. MarketBeat recorded 9 mentions for Guardant Health and 6 mentions for Chemed. Guardant Health's average media sentiment score of 0.27 beat Chemed's score of 0.15 indicating that Guardant Health is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Chemed	0 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Guardant Health	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

Summary

Guardant Health beats Chemed on 9 of the 17 factors compared between the two stocks.

How does Chemed compare to Tempus AI?

Chemed (NYSE:CHE) and Tempus AI (NASDAQ:TEM) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, valuation, risk, analyst recommendations, dividends, earnings, profitability and institutional ownership.

Chemed has a net margin of 10.60% compared to Tempus AI's net margin of -17.77%. Chemed's return on equity of 31.77% beat Tempus AI's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Chemed	10.60%	31.77%	18.90%
Tempus AI	-17.77%	-50.28%	-10.33%

Chemed has higher revenue and earnings than Tempus AI. Tempus AI is trading at a lower price-to-earnings ratio than Chemed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Chemed	$2.53B	2.58	$265.24M	$19.91	25.07
Tempus AI	$1.43B	8.94	-$245.03M	-$1.44	N/A

Chemed has a beta of 0.51, meaning that its share price is 49% less volatile than the broader market. Comparatively, Tempus AI has a beta of 3.54, meaning that its share price is 254% more volatile than the broader market.

95.9% of Chemed shares are held by institutional investors. Comparatively, 24.2% of Tempus AI shares are held by institutional investors. 3.3% of Chemed shares are held by insiders. Comparatively, 24.3% of Tempus AI shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Chemed currently has a consensus price target of $554.60, suggesting a potential upside of 11.11%. Tempus AI has a consensus price target of $71.05, suggesting a potential upside of 0.17%. Given Chemed's higher probable upside, research analysts plainly believe Chemed is more favorable than Tempus AI.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Chemed	0 Sell rating(s)	5 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.29
Tempus AI	2 Sell rating(s)	9 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.41

In the previous week, Tempus AI had 5 more articles in the media than Chemed. MarketBeat recorded 11 mentions for Tempus AI and 6 mentions for Chemed. Tempus AI's average media sentiment score of 0.82 beat Chemed's score of 0.15 indicating that Tempus AI is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Chemed	0 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Tempus AI	5 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Chemed beats Tempus AI on 9 of the 16 factors compared between the two stocks.

Get Chemed News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CHE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CHE vs. The Competition

Export

Metric	Chemed	Healthcare Providers & Services Industry	Healthcare Sector	NYSE Exchange
Market Cap	$6.51B	$9.81B	$7.16B	$22.94B
Dividend Yield	0.56%	2.61%	2.53%	3.72%
P/E Ratio	25.07	34.10	275.02	28.60
Price / Sales	2.58	4.87	635.97	14.91
Price / Cash	20.20	115.75	76.38	37.72
Price / Book	7.22	5.11	11.22	4.72
Net Income	$265.24M	$315.68M	$3.50B	$1.07B
7 Day Performance	-1.87%	-0.38%	-0.89%	0.35%
1 Month Performance	-2.78%	-1.97%	-4.42%	-2.94%
1 Year Performance	16.26%	12.76%	7.03%	9.25%

Chemed Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CHE Chemed	4.4455 of 5 stars	$499.14 +0.2%	$554.60 +11.1%	+15.8%	$6.51B	$2.53B	25.07	15,811	News Coverage Analyst Upgrade
MEDP Medpace	2.7725 of 5 stars	$620.51 +3.5%	$602.27 -2.9%	+18.0%	$16.73B	$2.78B	36.37	6,200	Analyst Forecast
DGX Quest Diagnostics	4.3467 of 5 stars	$231.97 -0.6%	$237.08 +2.2%	+27.4%	$25.75B	$11.56B	24.62	57,000	Ex-Dividend Analyst Upgrade
LH Labcorp	3.8136 of 5 stars	$308.52 +0.0%	$337.73 +9.5%	+12.4%	$25.02B	$13.95B	25.52	71,000	Analyst Upgrade
GH Guardant Health	2.3195 of 5 stars	$187.22 +5.3%	$188.54 +0.7%	+156.6%	$23.86B	$982.02M	N/A	2,506	Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:CHE) was last updated on 10/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Chemed (CHE) Competitors